49.24
-15.34%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arrowhead Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Arrowhead Pharmaceuticals is based in Pasadena, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ARWR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 September 2025, it reported revenue of $829.4m and a net loss of $1.6m. At that date it held total assets of $1.39bn and shareholders' equity of $466.1m.
The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.
There are currently 18 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3). In addition, the company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year.
The Company recently achieved a transformational milestone with its first commercial launch in 2025, when the U.S. Food and Drug Administration ("FDA") approved REDEMPLO® (plozasiran) as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome ("FCS"). Additionally, phase 3 studies (SHASTA-3, SHASTA-4 and SHASTA-5) for severe hypertriglyceridemia ("sHTG") have been fully enrolled and the Company plans to file a supplemental NDA for this indication in 2026, pending successful completion of Phase 3 clinical studies. The Company has built a commercial organization to support marketing in FCS, a rare disease, and plans to progressively build its commercial capabilities to also support marketing in sHTG, a higher prevalence disease which will require a larger commercial footprint.
Quoted from its 10-K, filed 25 Nov 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Dec 1993
- Employees
- 711
- Website
- arrowheadpharma.com ↗
- Head office
- 177 E COLORADO BLVD, PASADENA, CA, 91105
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Christopher AnzaloneChairman of the Board, President, Chief Executive Officer, since 2007$12.4m
- Mr. Daniel ApelChief Financial Officer
- Mr. Patrick O'BrienChief Operating Officer, General Counsel, Company Secretary$3.9m
- Mr. James HamiltonChief of Discovery and Translational Medicine, since 2023$3.5m
- Mr. William WaddillLead Independent Director$470,833
- Dr. Mauro FerrariIndependent Director$460,833
- Mr. Douglas IngramIndependent Director
- Dr. Hongbo LuIndependent Director$804,999
- Dr. Adeoye OlukotunIndependent Director$460,833
- Dr. Michael PerryIndependent Director$460,833
- Ms. Victoria VakienerIndependent Director$460,833
- Mr. Vincent AnzaloneInvestor Relations, since 2018
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 48
- Social
- 72
- Governance
- 22
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arrowhead Pharmaceuticals Inc has several strengths that contribute to its success:
Weaknesses
- Despite its strengths, Arrowhead Pharmaceuticals Inc also faces certain weaknesses:
Opportunities
- Arrowhead Pharmaceuticals Inc can capitalize on the following opportunities:
Threats
- Arrowhead Pharmaceuticals Inc should be mindful of the following threats:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.